But this particular Riesling, I don't know the name of it, so sorry
Choosing anti-inflammatory protein sources is key
Furthermore, long-term fracture risk, bone microarchitecture changes, and implant survival in GLP-1 agonist users remain poorly studied
Medicaid (Aetna Better Health): Tier 2, $0 copay with PA for diabetes
Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
Monitor renal function in patients reporting adverse reactions to Victoza that could lead to volume depletion, especially during dosage initiation and escalation of Victoza Severe Gastrointestinal Adverse Reactions: Use of GLP-1 receptor agonists, including Victoza , has been associated with gastrointestinal adverse reactions, sometimes severe